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Abstract  
Background: Functional and mental health impairments that adults with attention-
deficit/hyperactivity disorder (ADHD) experience may be exacerbated by regular substance use and 
co-morbidity with substance use disorders (SUD). This may be especially true during young 
adulthood, which represents a critical stage of life associated with increased substance use and 
associated problems. However, previous studies investigating the association between ADHD and 
substance use and SUD have demonstrated inconsistent results, probably due to methodological 
limitations (e.g., small and non-representative samples). Thus, the relationship of ADHD with 
substance use and related disorders remains unclear. The aim of the present study was to examine the 
association between ADHD and both the use of licit and illicit substances and the presence of SUD in 
a large, representative sample of young men. 
 
Methods: The sample included 5,677 Swiss men (mean age 20 ± 1.23 years) who participated in the 
Cohort Study on Substance Use Risk Factors (C-SURF). ADHD was assessed using the adult ADHD 
Self Report Screener (ASRS). The association between ADHD and substance use and SUD was 
assessed for alcohol, nicotine, cannabis and other illicit drugs, while controlling for socio-
demographic variables and co-morbid psychiatric disorders (i.e., major depression (MD) and anti-
social personality disorder (ASPD)). 
 
Results: Men with ADHD were more likely to report having used nicotine, cannabis and other illicit 
drugs at some time in their life, but not alcohol. ADHD was positively associated with early initiation 
of alcohol, nicotine and cannabis use, the risky use of these substances, and the presence of alcohol 
use disorders, and nicotine and cannabis dependence. Additionally, our analyses revealed that these 
patterns are also highly associated with ASPD. After adjusting for this disorder, the association 
between ADHD and licit and illicit substance use and the presence of SUDs was reduced, but 
remained significant.  
 
Conclusions: Our findings suggest that adult ADHD is significantly associated with a propensity to 
experiment with licit and illicit substances, especially at earlier ages, to exhibit risky substance use 
patterns, and to subsequently develop SUDs. Preventive strategies that include early intervention and 
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addressing co-morbidity with ASPD may be crucial to reducing substance use and the development of 
pathological substance use patterns in young men affected by ADHD and, thus, helping to prevent 
further illness burden later in life.  
 
Key words: adult attention-deficit/hyperactivity disorder, substance use, substance use disorder, 
alcohol, nicotine, cannabis 
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Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric 
disorders in childhood (average prevalence: 5.2%; 6.1% in boys, 3.3% in girls) (Steinhausen et al., 
1998) and often persists into adulthood (Faraone et al., 2000; Ebejer et al., 2012). Recent studies 
estimated the prevalence in adults at around 4.0% (Estévez et al., 2014; Fayyad et al., 2007). ADHD 
can significantly affect mental health and functioning in many life domains over one’s entire life span 
(Brod et al., 2012; Das et al., 2012; de Zwaan et al., 2012; Ebejer et al., 2012). One area of public 
health concern is the relationship between ADHD and both substance use and substance use disorders 
(SUD). Some study results suggest that the presence of ADHD predicts the use of licit and illicit 
substances and, especially, of related SUD (Baker et al., 2012; Klein et al., 2012; De Alwis et al., 
2014); for review see (Charach et al., 2011; Lee et al., 2011). This is problematic, as regular substance 
use and corresponding disorders can lead to further impairments in life domains wherein those with 
ADHD already experience significant disadvantages. 
The transition from adolescence to adulthood is a particularly critical stage of life for all young adults 
because it is characterised by considerable changes in every life domain (e.g., entering the workforce) 
(Gotham et al., 2003). Additionally, substance use and associated problems often increase during these 
years (Rehm et al., 2006; Toumbourou et al., 2007). Due to their symptoms, individuals with ADHD 
may experience more difficulties adapting to new situations and coping with the many challenges this 
life period introduces. Under these circumstances, they may be more vulnerable to using licit and 
illicit substances, and to developing SUD (Baker et al., 2012). For all these reasons, achieving better 
insights into the relationship between ADHD and substance use and related disorders in the young 
may be crucial to preventing negative consequences and reducing the burden of ADHD later in life. 
A considerable body of research already exists investigating this relationship. However, results are 
inconsistent, with some studies failing to identify the aforementioned link between ADHD and 
substance use and related disorders, or only identifying an association for some substances (Lee et al., 
2011; Galera et al., 2013; Madsen & Dalsgaard, 2014). Lack of sample representativeness and small 
sample sizes may have contributed to these inconsistent results. Indeed, previous studies were often 
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limited by the use of convenience samples (e.g., from patient or student populations). Also because of 
the small samples, not all studies adjusted for potential confounders (Charach et al., 2011; Lee et al., 
2011). Thus, it remains unclear if ADHD really is predictive of substance use and SUD, or if this link 
is mediated by other variables like co-morbid psychiatric disorders or specific socio-demographic 
characteristics. Another limitation of previous studies is that most investigated individuals during 
childhood and early adolescence, when the absence of positive associations between ADHD and SUD 
might merely be because subjects were too young (Kessler et al., 2005); for a review of limitations, 
see (Charach et al., 2011; Galera et al., 2013). Furthermore, previous studies mainly focused on the 
relationship between ADHD and SUD. Few examined the influence of ADHD on more general 
substance use patterns — like the age of first use, lifetime prevalence, and the risky use of particular 
substances — that may be precursors to SUD. Identifying target use patterns may help to prevent the 
development of substance-related pathology in individuals with ADHD.  
The aim of the present study was to clarify the association between adult ADHD and 1) substance use, 
and 2) SUD. This included investigating more general use patterns, thereby providing information 
about experimentation with and risky use of particular substances. To avoid some of the limitations of 
previous studies, a large, representative sample of young Swiss men was surveyed. Due to the 
contradicting previous findings concerning the role of other factors, this study examined whether 
ADHD was associated with the outcomes of interest independent of relevant co-morbid psychiatric 
disorders (i.e., antisocial personality disorder (ASPD) and major depression (MD) (Estévez et al., 
2014; Regier et al., 1990)) and socio-demographics. We hypothesized that ADHD in young men 
would be significantly associated with substance use (experimentation and risky use) and SUDs, 
independent of other factors.  
 
Methods 
Study design 
Data were extracted from the ‘Cohort Study on Substance Use Risk Factors’ (C-SURF), designed to 
assess substance use patterns within a cohort of young Swiss men. The Ethics Committee for Clinical 
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Research at Lausanne University Medical School (protocol number 15/07) approved the study 
protocol and informed written consent was obtained from all participants.  
The sample was recruited at three of the six centres that recruit men for military service, covering 21 
of 26 Swiss cantons (recruitment: August 2010 to November 2011). Switzerland has a mandatory 
army recruitment process, such that all young men are called up at roughly 19 years of age to 
determine their eligibility for military or civil service, versus no service. As no pre-selection to army 
conscription exists, this procedure allowed us to access a representative sample of young Swiss men. 
The army centres were used only to enrol participants into the study; both the study itself and the 
men’s decision to participate were entirely independent of the army. Data were drawn from baseline 
assessments collected between September 2010 and March 2012. 
 
Participants 
The present study used data from 5,677 subjects. Detailed information about participation is presented 
in Figure 1. As reported previously (Studer et al., 2013), participants and non-participants differ with 
respect to some substance use outcomes. However, these differences are small and statistically- 
significant largely due to the large sample, suggesting little effect of non-response on reported results. 
To avoid losing further data, subjects missing values on certain outcome variables were not excluded 
from analyses involving other variables. The exact number of participants used for each outcome 
variable is shown in Table 1. 
 
Independent Variables 
Adult ADHD 
ADHD over the past 12 months was assessed using the 6-item Adult ADHD Self-Report Scale 
Screener (ASRS-v1.1), developed based on the DSM-IV diagnostic criteria by the World Health 
Organization (WHO) (Kessler et al., 2005; Kessler et al., 2007). Responses were summated and 
dichotomized into “no ADHD” (scores 0-13) and “ADHD” (scores 14-24). Participants who failed to 
answer at least three items from the ASRS Screener were excluded (n = 20, 0.4%); meanwhile, 
missing responses for participants failing to answer only one or two items were replaced utilizing 
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nearest-neighbour hot-deck imputations, via a random recursive partitioning (RRP) dissimilarity 
matrix, implemented within the RRP package (Iacus & Porro, 2007) running in version 2.15 of the R 
statistical environment (R Team Core Development, 17). 
 
Co-morbid disorders  
MD was assessed using the Major Depressive Inventory (ICD-10) – WHO-MDI (Bech et al., 2001; 
Olsen et al., 2003). Responses were dichotomised to indicate the absence or presence of each 
symptom and coded as “no MD” or “MD”. MD was defined as the presence of at least five MDI 
items, with either item 1 or item 2 required among those five items (Bech et al., 2001). Participants 
were excluded when more than two items were unanswered. 
ASPD was measured using the Mini International Neuropsychiatric Interview (MINI plus, (Sheehan et 
al., 1998)). Responses were dichotomised to indicate the absence or presence of each symptom and 
coded as “no ASPD” or “ASPD”. ASPD was defined as the presence of at least two symptoms before 
the age of 15 and three afterwards. Participants were excluded when more than two of the questions 
were unanswered.  
 
Socio-demographic variables  
Socio-demographic variables included age (“younger than 20 years” vs. “20 years or older”), linguistic 
region (“German-” vs. “French-speaking”), residence (“rural’ vs. “urban”), highest achieved education 
(“primary school” vs. “secondary vocational school” vs. “high school/university”), degree of financial 
autonomy (“financial autonomy” vs. “partial financial dependency” vs. “financial dependency”), 
maternal education (“primary school” vs. “secondary vocational school” vs. “high school/university”) 
and family affluence (“above average” vs. “average” vs. “below average”).  
 
Outcome variables 
The association between ADHD and substance use and SUD was assessed for alcohol, nicotine, 
cannabis and other illicit drugs. Outcomes of interest were: 1) variables related to subjects’ 
experimentation with these substances (i.e., age at first use and lifetime use); 2) risky use of alcohol, 
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nicotine and cannabis; and 3) the presence of SUD (again for alcohol, nicotine and cannabis). Only 
lifetime use was assessed for illicit drugs besides cannabis, because their use is rare.  
 
Experimentation with substance use 
For alcohol, nicotine and cannabis use, questions about the respective age at first use were assessed 
and answers categorized into “very early-onset” (≤ age 12), “early-onset” (13 through 15), “late-onset” 
(≥ age 16) and “no use”. 
Additionally, these questions were used to specify whether conscripts had ever 1) consumed alcohol, 
2) smoked a cigarette, or 3) used cannabis. Lifetime use of each of the afore-mentioned substances 
was coded as “no use” or “at least one-time use”. Additionally, participants were asked whether they 
had ever used any illicit drugs other than cannabis (for a list of all included illicit drugs, see Baggio et 
al., 2013). Illicit drug use also was coded as “no use” or “at least one-time use”. 
 
Risky substance use 
Risky alcohol use was assessed using questions about the usual quantity and frequency of alcohol 
consumption and the frequency of risky single-occasion drinking (RSOD), defined as consuming at 
least six standard drinks on a single occasion, over the preceding 12 months. This variable was 
dichotomized into “no risky use” (including those who never or only occasionally drink alcohol) 
versus “risky use” (including conscripts reporting either RSOD at least monthly or risky-volume 
drinking). Risky-volume drinking was defined as at least 21 standard drinks per week. For detailed 
information about the assessment and coding of these variables, see (Gmel et al., 2010). 
Risky nicotine use was dichotomized into “no risky use” (including those who never or only 
occasionally smoke cigarettes) versus “risky use” (smoking at least one cigarette daily). Risky 
cannabis use was dichotomized into “no risky use” (using cannabis at most once per week or not at 
all) versus “risky use” (using cannabis more than once weekly). 
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SUD 
Alcohol abuse and dependence were assessed via questionnaires (Knight et al., 2002) based upon 
DSM-IV diagnostic criteria. The questions were adapted from the Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA) (Bucholz et al., 1994; Hesselbrock et al., 1999). Abuse was defined 
as a positive response to any of the four abuse criteria and the absence of dependence. Dependence 
was defined as a positive response to any three or more of seven dependence criteria (Knight et al., 
2002). For our purposes, a variable was created with the followed categories: “no abuse or 
dependence” (also including those who consume no alcohol) and “abuse or dependence”.  
Nicotine dependence was assessed using the 6-item Fagerström Test for Nicotine Dependence (FTND 
revised version; (Heatherton et al., 1991; Bleich et al., 2002). Summation scores were categorized into 
“no or very mild dependence” (scores 0-2), “mild dependence” (scores 3-4), “moderate dependence” 
(score 5), “severe dependence” (scores 6-7) and “very severe dependence” (scores 8-10). To reduce 
the number of outcomes, the first three and last two categories were grouped together, generating a 
binary variable: “no use to moderate dependence” vs. “severe dependence”.  
Cannabis dependence was measured with the 10-item Cannabis Use Disorder Identification Test 
(CUDIT revised version; (Adamson & Sellman, 2003)). Three of the items were modified according 
to Annaheim et al. (Annaheim et al., 2010). Answers were summated and dichotomized into “no 
dependence” (scores 0-7) and “dependence” (scores 8-40).  
 
Statistical analysis  
All statistical analyses reported below, were performed using the statistical package SPSS 20.0. Socio-
demographic, co-morbidity, and substance use characteristics were compared between participants 
with and without ADHD using Pearson chi-square analysis. To examine the association between 
ADHD and substance use and SUD, binomial and multinomial logistic regression analyses were 
performed using ADHD as a predictor. From this, unadjusted and adjusted odd ratios (OR) were 
calculated. In the adjusted models 1) socio-demographic variables alone, and 2) socio-demographic 
characteristics and co-morbid disorders were included. To further identify associations between co-
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morbid disorders and substance use outcomes, unadjusted regression analyses also were performed for 
ASPD and MD.  
 
Results 
For socio-demographic characteristics, co-morbidity variables, and substance use outcomes for 
participants with and without adult ADHD, see Table 1. Detailed regression analysis results for all 
investigated substances are presented in Tables 2 for lifetime use, risky substance use and SUD, and in 
Table 3 for age of first use. Unadjusted and adjusted ORs and 95% confidence intervals (95% CI) for 
ADHD, ASPD and MD are shown. 
 
Alcohol 
No significant difference between participants with and without ADHD was identified in terms of ever 
having used alcohol (Table 2). However, more conscripts with ADHD reported an early or very early 
age of alcohol use onset than those without ADHD (Table 3). Furthermore, young men with ADHD 
were more likely to report risky alcohol use and alcohol use disorders (Table 2). Adjusting for socio-
demographic variables did not substantially change the results for any of the alcohol-related outcomes 
(data not shown). When also adjusting for ASPD and MD, the positive association between ADHD 
and risky alcohol use only decreased slightly. In contrast, the ORs for the relationships of ADHD with 
age of first alcohol use and with alcohol use disorders, although still significant, were reduced. 
Sensitivity regression analyses using the co-morbid disorders (ASPD and MD) separately revealed 
that this reduction was mainly due to the adjustment for ASPD and not MD. The effect of ASPD 
remained stable for both outcomes even after adjusting for socio-demographics, MD and ADHD. In 
contrast to ADHD and ASPD, MD exhibited an inverse association with lifetime alcohol use.  
 
Nicotine 
Young men with ADHD were more likely to report having smoked a cigarette at some time in their 
life (Table 2) and having started smoking at a very early age than men without this disorder (Table 3). 
Additionally, more men with ADHD reported risky nicotine use and nicotine dependence (Table 2). 
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Adjusting for socio-demographic variables did not change these results (data not shown), while also 
correcting for co-morbid disorders reduced the ORs for all outcomes. Odds ratios were reduced but 
remained significant for age of onset, ever having smoked, and risky nicotine use. For nicotine 
dependence, only a trend was detected (p < .10). The observed reduction was due to the inclusion of 
ASPD in the model, which was significantly associated with all nicotine-related outcomes, even after 
correcting for all other variables. Conversely, MD was not associated with any nicotine-related 
outcome except nicotine dependence.  
 
Cannabis and other illicit drugs 
More young men with ADHD reported having used cannabis and other illicit drugs at some time than 
those without ADHD (Table 2). They also more often reported an early or very early age of first 
cannabis use and were less often non-users than men without ADHD (Table 3). Conscripts with 
ADHD also more often admitted to risky cannabis use and cannabis dependence (Table 2). Similar to 
alcohol- and nicotine-related outcomes, the positive association between ADHD and outcomes related 
to illicit substance use did not change after correcting for socio-demographic variables (data not 
shown), but did after adjusting for co-morbid disorders. For co-morbid conditions, the effect of ADHD 
was reduced but still significant for most outcomes. Only the positive association between ADHD and 
early-onset cannabis use failed to achieve statistical significance after this correction. As for alcohol- 
and nicotine-related outcomes, ASPD displayed a constant association with most drug-related 
variables, except for cannabis dependence and very early onset of cannabis use, for which ORs were 
reduced after adjustments were made. MD was only related to cannabis dependence and the use of 
other illicit drugs.  
 
A post-hoc power analysis conducted with G*power (Faul et al., 2009) revealed that, for a type 1 error 
of 5% and a sample of 5677 participants, the power to detect an OR of 1.5, which corresponds to a 
small effect size (Rosenthal, 1996), is 83.3% if the response probability of the dependent variable is 
4%. For this prevalence, medium effects (OR=2.5, (Rosenthal, 1996)) can be detected with a power of 
100%. This is true under the assumption that the dependent variable and independent variable of 
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interest are correlated with control variables to R2 = 0.20. For a dependent variable with a prevalence 
of 3%, only medium effect sizes (OR = 2.5) would yield sufficient power of 80%. In fact, the power 
for this case would again be 100%. The prevalence rates of nearly all the dependent variables used in 
this study were considerably greater than 4%. Thus, the sample size was more than sufficient to detect 
small effect sizes with a higher power than the standard level of 80%. 
 
Discussion 
The present study investigated the association between adult ADHD and both the use of licit and illicit 
substances and the presence of SUD. Since young adulthood represents a critical stage of life wherein 
substance use and associated problems often increase, associations were investigated in a large, 
representative sample of young men drawn from the general Swiss population. 
Young men with ADHD were more likely to have used nicotine, cannabis and other illicit drugs at 
some time in their life, but no more likely to have consumed alcohol. These findings are consistent 
with a previously-reported meta-analysis on substance use and ADHD (Lee et al., 2011) that included 
27 prospective follow-up studies that followed children into adolescence and/or adulthood, but mainly 
used small, selective samples. Our results also agree with findings reported recently for a 
representative sample of the U.S. population (NESARC project; (De Alwis et al., 2014), which 
included a broader age range than the present study (18 years and older, mean age: 37.5 to 49.2 
depending on the subgroups studied), but also accounted for co-morbid disorders and relevant socio-
demographic characteristics. Additionally, the presence of ADHD was associated with the age of first 
use of nicotine, cannabis and alcohol. Compared with young men without ADHD, those with this 
disorder were more likely to try alcohol while still 15 years old or younger and to use nicotine and 
cannabis before age 13. Altogether, these results suggest that the presence of ADHD may contribute to 
a propensity to experiment with licit and illicit substances, and that this is especially true at early ages.  
Early substance use initiation has repeatedly been linked to the development of SUD (Ernst et al., 
2006; Odgers et al., 2008; Gmel et al., 2010). The early initiation patterns observed in our study, 
together with these previous reports, suggest that early initiation may be an important precursor of 
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pathological substance use patterns in men with ADHD. Therefore, preventive interventions should be 
implemented during childhood and early adolescence in males with ADHD to reduce their likelihood 
of developing later pathological substance use patterns.  
ADHD was also associated with risky consumption of alcohol, nicotine and cannabis. These results 
are in accordance with previous findings and may be related to the difficulty those with ADHD have 
regulating their consumption. For instance, in one study on college students (Baker et al., 2012), 
ADHD sufferers were more likely to report difficulties stopping their drinking once started, leading to 
more risky drinking. Men with ADHD who have tried nicotine also appear to be more likely to 
become regular smokers than those who have not, as demonstrated in a cross-sectional study of 
adolescents (Madsen & Dalsgaard, 2014). In addition to difficulties controlling substance use, several 
studies indicated that not only nicotine, but also cannabis and other illicit drugs are often used by 
individuals with ADHD as self-medication to reduce their symptoms (Wilens, 2007; Wilens et al., 
2007; Frei et al., 2010; Silva et al., 2014), which may further increase both their likelihood of using 
these substances regularly and their subsequent risk of SUD. 
Indeed, consistent with previously-published findings (Charach et al., 2011; Lee et al., 2011; De 
Alwis et al., 2014), we also observed a positive association between ADHD and the presence of SUD, 
with the probability of an alcohol or cannabis use disorder approximately two times greater among 
men with ADHD than those without. However, contrary to most studies investigating the contribution 
of ADHD to nicotine dependence, our results demonstrate only a borderline significance after 
adjusting for co-morbidity and socio-demography. This may be due to the small number of subjects 
we had in the “severe dependency” category and to our use of a binary variable for analysis. Indeed, 
additional multinomial regression analysis using four categories (“no or very mild dependence”, “mild 
dependence”, “moderate dependence”, “severe dependence”) revealed a significant association 
between ADHD and severe nicotine dependence, but not with mild or moderate dependency (data not 
shown). Therefore, in young men, ADHD may contribute to nicotine dependence at least in more 
extreme cases. Considering that the impairments that adults with ADHD experience can have a 
cumulative effect over their life span (Brod et al., 2012) and may even be exacerbated by co-morbidity 
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with SUD, the high frequency of SUD already observed in our young subjects is alarming. Further 
efforts should be undertaken to prevent the development of such disorders in young males with 
ADHD. 
When controlling for co-morbid disorders, our analyses revealed that the association between ADHD 
and licit and illicit substance use and the development of SUD was reduced when adjusting for ASPD. 
As such, the positive association between ADHD and substance use patterns reported in previous 
studies that did not control for co-morbidity, may be partially mediated by ASPD. Consistent with our 
results, some of those few studies that did control for co-morbidity identified the increased use of licit 
and illicit substances and the presence of SUD in subjects who also reported conduct problems and 
antisocial behaviour during childhood and adolescence (Lee et al., 2011). A recent meta-analysis 
(Serra-Pinheiro et al., 2013) addressing the relationship between ADHD and the use of illicit drugs 
and SUD found that, although the risk of these use patterns was higher among those with versus 
without ADHD, differences were not statistically significant after correcting for conduct problems and 
antisocial behaviours. However, as suggested by the authors, it is possible that the power of this meta-
analysis was insufficient to detect any other than strong associations. In fact, after adjusting for ASPD, 
we identified weak or moderate associations between ADHD and substance use and SUD, whereas for 
ASPD such associations were greater (i.e., moderate or large according to (Rosenthal, 1996)). Thus, 
insufficient power might explain the lack of significance observed in previous studies. Investigations 
using large enough samples to also detect small or medium effects could be crucial to elucidating 
whether ADHD is associated with particular substance use patterns and the roles of conduct problems 
and antisocial behaviours in such associations. Additionally, our findings suggest that males with 
ADHD may benefit from interventions that also address the association between ASPD and substance 
use and misuse. 
 
Study limitations 
The following limitations of our study must be considered. First, women were excluded from our 
sample, though evidence exists that women differ from men in the association between ADHD and 
substance use and SUD (Galera et al., 2010). Second, our assessment of ADHD, co-morbid disorders 
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and all SUD was performed using self-reports and did not include any confirmatory diagnostic 
assessment. However, we only used well-validated and previously-used scales (Heatherton et al., 
1991; Bucholz et al., 1994; Lecrubier et al., 1998; Hesselbrock et al., 1999; Bech et al., 2001; Olsen et 
al., 2003; Kessler et al., 2007; Annaheim et al., 2010). Third, the medical history for ADHD and 
mental disorders was not assessed. Therefore, we do not know the clinical status of our study 
participants or whether they had received or continued to receive any treatment.  Fourth, with respect 
to reporting age of first use and lifetime use, recall bias cannot be excluded. Finally, the cross-
sectional data collection prevents us from drawing causal inferences. 
 
In summary, our findings suggest that young men with ADHD are susceptible to experimenting with 
different licit and illicit substances, especially at earlier ages, and more likely to exhibit risky use 
patterns and ultimately develop some substance use disorder. These patterns are also highly associated 
with ASPD. Therefore, early preventive interventions that address the ASPD co-morbidity issue might 
be crucial to preventing the development of SUDs, which themselves often increase illness burden in 
men affected by ADHD. 
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Table 1 Socio-demographic characteristics, co-morbid variables and substance use outcomes according to adult ADHD. 
  
  All Participants  
Participants 
without ADHD  
Participants 
with ADHD     
  Totala n % n % n % Χ2  p 
Alcohol                   
Age of onset  5677                 
no use   189 3.3 180 3.3 9 3.9 17.01 <.001 
late (≥16)   1450 25.5 1413 25.9 37 16.2     
early (13-15)   3343 58.9 3204 58.8 139 61.0     
very early (≤12)   695 12.2 652 12.0 43 18.9     
Ever consumed alcohol 5677 5488 96.7 5269 96.7 219 96.1 0.28 .595 
Risky alcohol use 5646 2633 46.6 2504 46.2 129 57.1 10.32 0.001 
Alcohol abuse/dependence 5677 2084 36.7 1949 35.8 135 59.2 51.76 <.001 
                    Nicotine                   
Age of onset  5665                 
no use   2214 39.1 2153 39.6 61 26.8 30.88 <.001 
late (≥16)   1406 24.8 1354 24.9 52 22.8     
early (13-15)   1461 25.8 1390 25.6 71 31.1     
very early (≤12)   584 10.3 540 9.9 44 19.3     
Ever smoked a cigarette 5665 3451 60.9 3284 60.4 167 73.2 15.16 <.001 
Risky nicotine use 5658 1189 21.0 1113 20.5 76 33.3 21.72 <.001 
Nicotine dependence 5342                 
very mild to moderate   5160 96.6 4958 96.8 202 91.4 18.87 <.001 
severe   182 3.4 163 3.2 19 8.6     
                    Cannabis                   
Age of onset 5677                 
no use   2974 52.4 2896 53.1 78 34.2 51.62 <.001 
late (≥16-20)   1642 28.9 1570 28.8 72 31.6     
early (13-15)   936 16.5 872 16.0 64 28.1     
very early (≤12)   125 2.2 111 2.0 14 6.1     
Ever used cannabis 5669 2703 47.7 2553 46.9 150 66.1 32.09 <.001 
Risky cannabis use 5664 539 9.5 491 9.0 48 21.1 37.14 <.001 
Cannabis dependence 5639 492 8.7 440 8.1 52 23.5 63.30 <.001 
                    Other illicit drugs                   
Ever used other illicit drugs 5657 988 17.5 914 16.8 74 32.6 37.58 <.001 
                    
Co-morbid disorders                   
ASPD 5677 931 16.4 848 15.6 83 36.4 69.33 <.001 
MD 5677 147 2.6 116 2.1 31 13.6 114.10 <.001 
                    
Socio-demographics                   
Age 5677                 
<20   3407 60.0 3291 60.4 116 50.9 8.26 .004 
≥20   2270 40.0 2158 39.6 112 49.1     
Linguistic region 5677                 
German   2569 45.3 2499 45.9 70 30.7 20.30 <.001 
French   3108 54.7 2950 54.1 158 69.3     
Residence 5677                 
rural   1872 33.0 1807 33.2 65 28.5 2.14 .143 
urban   3805 67.0 3642 66.8 163 71.5     
Education 5677                 
primary school   2843 50.1 2729 50.1 114 50.0 5.76 .056 
secondary vocational school 1626 28.6 1573 28.9 53 23.2     
high school/university   1208 21.3 1147 21.0 61 26.8     
Financial autonomy 5677                 
financial autonomy   1336 23.5 1299 23.8 37 16.2 9.30 <0.010 
partial financial dependency 2424 42.7 2327 42.7 97 42.5     
financial dependency   1917 33.8 1823 33.5 94 41.2     
Mother's education 5677                 
primary school   766 13.5 724 13.3 42 18.4 16.41 <.001 
secondary vocational school 3536 62.3 3423 62.8 113 49.6     
high school/university   1375 24.2 1302 23.9 73 32.0     
Family affluence/income 5677                 
above average   2525 44.5 2430 44.6 95 41.7 1.62 .444 
average   2334 41.1 2240 41.1 94 41.2     
below   818 14.4 779 14.3 39 17.1     
 
 
ADHD: Attention deficit hyperactivity disorder; ASPD: Antisocial personality disorder; MD: Major depression; 
a Total number of participants (n) recorded for this variable, n varies slightly between variables due to missing data.  
 
Table 2 Logistic regression analyses with licit and illicit substances as outcomes. 
Licit substances         
  Ever consumed alcohol   Ever smoked a cigarette 
  Crude OR [CI] Adjusted OR [CI]a   Crude OR [CI] Adjusted OR [CI]a 
ADHD           
no 1.00 1.00   1.00 1.00 
yes 0.83 [0.42-1.65] 0.97 [0.48-1.99]   1.79 [1.33-2.42]*** 1.51 [1.11-2.06]** 
ASPD           
no 1.00 1.00   1.00 1.00 
yes 2.02 [1.22-3.34]** 2.19 [1.31-3.68]**   2.88 [2.43-3.41]*** 2.80 [2.36-3.33]*** 
MD           
no 1.00 1.00   1.00 1.00 
yes 0.34 [0.19-0.61]*** 0.38 [0.20-0.70]**   1.10 [0.78-1.54] 0.89 [0.63-1.28] 
  Risky alcohol use   Risky nicotine use 
  Crude OR [CI] Adjusted OR [CI]a   Crude OR [CI] Adjusted OR [CI]a 
ADHD           
no 1.00 1.00   1.00 1.00 
yes 1.55 [1.18-2.03]** 1.44 [1.09-1.90]*   1.94 [1.46-2.57]*** 1.62 [1.19-2.21]** 
ASPD           
no 1.00 1.00   1.00 1.00 
yes 2.29 [1.98-2.64]*** 2.27 [1.96-2.64]***   2.64 [2.27-3.08]*** 2.57 [2.19-3.01]*** 
MD           
no 1.00 1.00   1.00 1.00 
yes 1.00 [0.72-1.39] 0.91 [0.65-1.29]   1.59 [1.11-2.28]* 1.24 [0.84-1.84] 
 
Alcohol abuse/dependence   Nicotine dependence 
  Crude OR [CI] Adjusted OR [CI]a   Crude OR [CI] Adjusted OR [CI]a 
ADHD           
no 1.00 1.00   1.00 1.00 
yes 2.61 [1.99-3.41]*** 2.10 [1.58-2.80]***   2.86 [1.74-4.70]*** 1.68 [0.96-2.93]† 
ASPD           
no 1.00 1.00   1.00 1.00 
yes 3.56 [3.08-4.12]*** 3.51 [3.02-4.07]***   3.35 [2.46-4.56]*** 3.04 [2.20-4.19]*** 
MD           
no 1.00 1.00   1.00 1.00 
yes 1.46 [1.05-2.03]* 1.14 [0.80-1.62]   5.14 [3.12-8.46]*** 3.83 [2.21-6.63]*** 
            Illicit substances         
  Ever used cannabis   Ever used other illicit drugs 
  Crude OR [CI] Adjusted OR [CI]a   Crude OR [CI] Adjusted OR [CI]a 
ADHD           
no 1.00 1.00   1.00 1.00 
yes 2.20 [1.67-2.92]*** 1.74 [1.30-2.34]***   2.39 [1.79-3.18]*** 
 
1.61 [1.18-2.21]** 
 
ASPD           
no 1.00 1.00   1.00 1.00 
yes 3.34 [2.86-3.89]*** 3.22 [2.76-3.77]***   3.70 [3.16, 4.33]*** 
 
3.58 [3.05-4.21]*** 
 
MD           
no 1.00 1.00   1.00 1.00 
yes 1.30 [0.94-1.81] 1.01 [0.71-1.44]   2.14 [1.50-3.06]*** 
 
1.63 [1.01-2.40]* 
 
  Risky cannabis use   Cannabis dependence 
  Crude OR [CI] Adjusted OR [CI]a   Crude OR [CI] Adjusted OR [CI]a 
ADHD           
no 1.00 1.00   1.00 1.00 
yes 2.70 [1.94-3.76]*** 1.84 [1.28-2.65]**   3.48 [2.51-4.82]*** 2.24 [1.56-3.24]*** 
ASPD           
no 1.00 1.00   1.00 1.00 
yes 4.26 [3.52-5.14]*** 4.00 [3.29-4.86]***   5.33 [4.39-6.47]*** 4.94 [4.04-6.04]*** 
MD           
no 1.00 1.00   1.00 1.00 
yes 2.01 [1.30-3.12]** 1.35 [0.84-2.19]   3.00 [2.00-4.51]*** 2.00 [1.25-3.11]** 
ADHD: Attention deficit hyperactivity disorder; ASPD: Antisocial personality disorder; MD: Major depression; 
†p < .10, *p < .05, **p < .01, ***p < .001; OR: Odds ratio; CI: 95% confidence interval; a Adjusted for socio-demographic 
variables and co-morbid disorders. 
Table 3 Multinomial regression analyses with age of first use of alcohol, nicotine and cannabis as outcome. 
Alcohol use Very early-onset (≤ 12 years)a   Early-onset (13 to 15 years)a   No usea 
  Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b 
ADHD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 2.52 [1.61-3.95]*** 1.77 [1.10-2.84]*   1.66 [1.15-2.39]** 1.54 [1.05-2.24]*   1.91 [0.91-4.02]† 1.45 [0.67-3.14] 
ASPD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 5.26 [4.10-6.74]*** 5.16 [4.01-6.65]***   2.41 [1.96-2.98]*** 2.41 [1.95-2.98]***   1.14 [0.67-1.94] 1.04 [0.60-1.78] 
MD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 1.35 [0.81-2.25] 0.96 [0.56-1.65]   0.77 [0.52-1.15] 0.69 [0.46-1.04]†   2.67 [1.40-5.10]** 2.15 [1.10-4.19]* 
  
Nicotine use Very early-onset (≤ 12 years)a   Early-onset (13 to 15 years)a   No usea 
  Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b 
ADHD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 2.12 [1.40-3.21]*** 1.67 [1.08-2.59]*   1.33 [0.92-1.92] 1.19 [0.81-1.73]   0.74 [0.51-1.08] 0.79 [0.54-1.15] 
ASPD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 3.68 [2.92-4.64]*** 3.50 [2.76-4.43]***   2.20 [1.81-2.68]*** 2.17 [1.78-2.65]***   0.65 [0.52-0.80]*** 0.65 [0.52-0.81]*** 
MD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 1.52 [0.86-2.69] 1.04 [0.57-1.89]   1.21 [0.76-1.94] 0.99 [0.61-1.60]   1.07 [0.69-1.67] 1.12 [0.72-1.76] 
         
Cannabis use Very early-onset (≤ 12 years)a   Early-onset (13 to 15 years)a   No usea 
  Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b   Crude OR [CI] Adjusted OR [CI]b 
ADHD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 2.75 [1.50-5.03]*** 1.95 [1.02-3.74]*   1.60 [1.13-2.26]** 1.30 [0.90-1.87]   0.59 [0.42-0.81]*** 0.67 [0.48-0.93]* 
ASPD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 5.12 [3.52-7.44]*** 4.66 [3.18-6.83]***   2.74 [2.28-3.31]*** 2.64 [2.18-3.19]***   0.50 [0.41-0.59]*** 0.50 [0.42-0.60]*** 
MD                 
no 1.00 1.00   1.00 1.00   1.00 1.00 
yes 2.07 [0.86-4.99] 1.16 [0.46-2.96]   1.55 [0.97-2.47]† 1.16 [0.71-1.89]   0.96 [0.65-1.43] 1.08 [0.72-1.62] 
ADHD: Attention deficit hyperactivity disorder; ASPD: Antisocial personality disorder; MD: Major depression; †p < .10, *p < .05, **p < .01, ***p < .001; OR: Odds ratio; CI: 95% confidence 
interval; a Reference category: late onset (16 years or later); b Adjusted for socio-demographic variables and co-morbid disorders.  
 Figure 1 Flow chart on participation 
 
